Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Pharma
Ipsen's liver disease drug Bylvay fails biliary atresia trial
Ipsen has reported the failure of liver disease med Bylvay in a phase 3 study that was designed to expand its patient population into biliary atresia.
Kevin Dunleavy
Jul 24, 2026 11:00am
With trial success, Gilead paves way for broader use of Livdelzi
Jun 2, 2026 10:55am
After Alfasigma licensing deal, Lynavoy picks up FDA nod
Mar 19, 2026 10:55am
Fierce Biotech
BioVie plans $20M IPO for spinout developing liver disease drug
Mar 17, 2026 5:18am
Esperion pays $75M for Corstasis and FDA-approved nasal spray
Mar 3, 2026 8:40am
Bausch tumbles as new version of Xifaxan fails ph. 3 trials
Jan 23, 2026 10:21am
